Assembly Biosciences Inc 's Revenue per employee fell on a trailing twelve month basis to $ 1,025,274, below the company average number of $477,564. Within the Healthcare sector Employees of 80 other companies have achieved higher revenue per employee. While Assembly Biosciences Inc 's total ranking has deteriorated compared to the previous quarter from 731 to 878. Assembly Biosciences Inc has 73 employees.
Innovative Therapeutics in Virology: Assembly Biosciences Unveils Promising Data on Capsid Assembly Modulators and Novel InhibitorsIn the realm of antiviral research, Assembly Biosciences has emerged as a significant player, particularly in the development of therapies aimed at combating hepatitis and herpes viruses. At a series of prestigious conferences, including the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting and the European Association for the Study of the Liver (EASL) Congress, the company presented cutting-edge data on their investigational drugs, showcasing their commitment to advancing medical science in virology. Next-Generation Capsid Assembly Modulator ABI-4334: Ensuring Safety and Efficacy At the recent AASLD The Liver Meeting, Assembly Biosciences showcased pivotal Phase 1b data for their next-generation capsid assembly modulator, ABI-4334. This compound demonstrated a favorable safety and tolerability profile, significantly contributing to its potential as a transformative agent in the treatment of hepatitis B. The data highlighted the drug s efficacy in inducing potent reductions in viral nucleic acids, a critical factor in managing and mitigating the viral load in infected patients.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
